Roche (Basel, Switzerland) and Blueprint Medicines Corporation announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialization outside the U.S., excluding Greater China. In the U.S., Genentech, a member of the Roche Group, will obtain co-commercialization rights to pralsetinib, Blueprint … [Read more...]